Susquehanna International Group
TOVX icon

Susquehanna International Group’s Theriva Biologics TOVX Stock Holding History

Susquehanna International Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-428
Closed -$4.61K – 13334
2023
Q4 		$4.61K Buy
+428
New +$5.27K ﹤0.01% 12131
2023
Q2 		– Sell
-427
Closed -$7.46K – 13146
2023
Q1 		$7.46K Buy
+427
New +$8.86K ﹤0.01% 12252
2022
Q4 		– Sell
-656
Closed -$16K – 13681
2022
Q3 		$16K Buy
656
+499
+318% +$19.2K ﹤0.01% 12680
2022
Q2 		$8K Buy
157
+82
+109% +$4.69K ﹤0.01% 12553
2022
Q1 		$5K Buy
+75
New +$5.11K ﹤0.01% 12818
2021
Q4 		– Sell
-88
Closed -$10K – 13914
2021
Q3 		$10K Buy
+88
New +$10.9K ﹤0.01% 12605
2021
Q1 		– Sell
-63
Closed -$6K – 12861
2020
Q4 		$6K Buy
+63
New +$5.52K ﹤0.01% 10929
2020
Q2 		– Sell
-984
Closed -$79K – 10935
2020
Q1 		$79K Buy
+984
New +$112K ﹤0.01% 9459
2019
Q4 		– Sell
-100
Closed -$11K – 10649
2019
Q3 		$11K Buy
100
+60
+150% +$7.25K ﹤0.01% 10012
2019
Q2 		$6K Sell
40
-9
-18% -$1.29K ﹤0.01% 10100
2019
Q1 		$8K Buy
+49
New +$8.12K ﹤0.01% 8664
2018
Q2 		– Sell
-4
Closed -$11K – 10431
2018
Q1 		$11K Buy
+4
New +$15.2K ﹤0.01% 9178
2017
Q3 		– Sell
-22
Closed -$107K – 9630
2017
Q2 		$107K Buy
22
+10
+83% +$49.8K ﹤0.01% 8659
2017
Q1 		$68K Sell
12
-7
-37% -$48.8K ﹤0.01% 8517
2016
Q4 		$128K Buy
+19
New +$195K ﹤0.01% 8956
2016
Q2 		– Sell
-48
Closed -$987K – 9332
2016
Q1 		$987K Buy
48
+21
+78% +$316K ﹤0.01% 5112
2015
Q4 		$536K Buy
+27
New +$571K ﹤0.01% 6632
2015
Q2 		– Sell
-12
Closed -$238K – 10466
2015
Q1 		$238K Buy
+12
New +$214K ﹤0.01% 8374
2014
Q2 		– Sell
-16
Closed -$360K – 10119
2014
Q1 		$360K Buy
+16
New +$331K ﹤0.01% 7306

Other funds holding TOVX

SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group's TOVX Position: Q1 2024 in Review

Susquehanna International Group sold out of Theriva Biologics (TOVX) in Q1 2024, closing a stake of 428 shares — an estimated $4.61K sold.

Susquehanna International Group first reported a position in TOVX in Q1 2014 and held it in 19 quarters. The position peaked at $987K in Q1 2016. 20 funds tracked by Wall St. Rank hold TOVX as of Q1 2024.

  • Susquehanna International Group reported no remaining Theriva Biologics position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 428 Theriva Biologics shares in Q1 2024, an estimated $4.61K.
  • Susquehanna International Group first reported a position in Theriva Biologics in Q1 2014 and held it in 19 quarters.
  • Susquehanna International Group's Theriva Biologics position peaked at $987K in Q1 2016.
  • 20 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.